Back to top

Jeet Mukherjee Initiates Buy on Ascentage Pharma, Citing 2027 NRDL Lisaftoclax Catalyst, Late???Stage Pipeline Readouts, and Cash Runway Through 2027

Jeet Mukherjee, an analyst from BTIG, maintained the Buy rating on Ascentage Pharma Group International Unsponsored ADR. The associated price targe...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: